Author： Slovacek Ladislav
Publisher： Humana Press, Inc
ISSN： 1357-0560
Source： Medical Oncology, Vol.27, Iss.4, 2010-12, pp. : 1431-1432
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Tamoxifen is an orally active selective estrogen receptor modulator that is used in the treatment of breast cancer and is currently the world's largest selling drug for that purpose. However, it has some side effects including hot flashes, menstrual irregularity, vaginal discharges, uterine bleeding, uterine endometrial cancer, hypercoagulability, steatosis hepatis, risk of trombembolism. Long-term data from clinical trials have failed to demonstrate a cardioprotective effect and beneficial effects on serum lipid profiles. Arrhythmia secondary to tamoxifen is very rare.
Related content
Gynecologic Oncology, Vol. 62, Iss. 1, 1996-07 ,pp. :
Access to resources
Recommend
Tamoxifen for breast cancer prevention - Arbiter:
European Journal of Cancer, Vol. 36, Iss. 2, 2000-01 ,pp. :